Oncology drugs report - Neupogen and Neulasta - filgrastim franchise - 1991-2015 analysis; 2016-2021 expectations

Oncology drugs report - Neupogen and Neulasta - filgrastim franchise - 1991-2015 analysis; 2016-2021 expectations

  • November 2016 •
  • 85 pages •
  • Report ID: 4397416 •
  • Format: PDF
“Oncology drugs report - Neupogen and Neulasta - filgrastim franchise - 1991-2015 analysis; 2016-2021 expectations” is a comprehensive report on Neupogen and Neulasta, two market leading drugs (by 2015 sales) used in the treatment of chemotherapy-induced febrile neutropenia. These drugs, both belonging to biotech giant Amgen, fall under the adjuvant category as they are used for support care in the treatment of cancer. They belong to the granulocyte colony-stimulating factor (GCSF) class.

The report gives an analysis of historical annual sales (from 1991-Q3-2016), historical quarterly sales (Q1-2011 to Q3-2016) and sales expectations (from 2016-2021). Our analysis broadly indicates that the drugs have not only captured the major part of the neutropenia market for the past two decades but are also likely to remain dominant over the next five years despite pending patent expiry in key geographies.

The report gives basic information about the drug, listing all details like brand name, date of approvals, mechanism of action, molecular structure, route of administration, and so on. It has interesting infographic descriptions of approval timelines of the two drugs and contains event trackers, which cover all the major events surrounding the drugs. Moreover, the report also gives details of biosimilar filings as well as key litigation actions of Amgen with companies involved with these biosimilars. It also provides details of number of clinical trials (by year and by phase), and so on. Summaries of the various sections are mentioned below.

Details of the sales analysis section
Historical annual sales analysis: Historical annual sales have been analysed in USD and JPY (for Japan) terms with the help of graphical representation of sales over 1991 to Q3-2016. The report has all the data in tabular format as well. We have highlighted key reasons for the sales trend in all the geographies listed.
Historical quarterly sales analysis: Additionally, we have sales analysis on quarterly basis for the past 15 quarters from Q1-2011 to Q3-2016. The quarterly data is in graphical as well as tabular format.

Expected sales analysis: The report has our expectations for sales of Neupogen and Neulasta over 2016-2021. We have highlighted key reasons for our expectations. All the historical as well as expected sales analysis is based on:
1. Total global sales
2. US sales
3. International sales (including Japan)
a. International sales (excluding Japan)
b. Japan sales

Other important details
Key event trackers: The report highlights key events that have taken place for Neupogen and Neulasta from 2005 to 2015. The event trackers give additional information about the key events that have driven sales for the drugs over this period.
Biosimilar filings: Neupogen’s patent has expired in all the markets while Neulasta still holds patent in Europe and Japan (but its patent has expired in the US). From this perspective, we have listed down the players who are marketing/filed for biosimilars indicating current/potential competition for Amgen. We have also given details of ongoing litigation of Amgen with some of the biosimilar companies.
Clinical trials numbers: The report provides details of number of ongoing clinical trials of filgrastim and pegfilgrastim that are in different phases phase III, phase III/II, phase II and phase I. It also gives number of currently ongoing trials for different years and phases.

News: We have listed news related to Neupogen and Neulasta that would impact their performance.

We are very sorry, but an error occurred.
Please contact support@reportbuyer.com if the problem remains.